View : 81 Download: 0

Current pharmacotherapies for atherosclerotic cardiovascular diseases

Title
Current pharmacotherapies for atherosclerotic cardiovascular diseases
Authors
Park, Jong-GilOh, Goo Taeg
Ewha Authors
오구택
SCOPUS Author ID
오구택scopus
Issue Date
2019
Journal Title
ARCHIVES OF PHARMACAL RESEARCH
ISSN
0253-6269JCR Link

1976-3786JCR Link
Citation
ARCHIVES OF PHARMACAL RESEARCH vol. 42, no. 3, pp. 206 - 223
Keywords
Atherosclerotic cardiovascular diseases (ASCVD)Pharmaceutical therapiesLipid-lowering drugsAnti-inflammatory therapiesStatinEzetimibePCSK9 inhibitorCanakinumabMethotrexate
Publisher
PHARMACEUTICAL SOC KOREA
Indexed
SCIE; SCOPUS; KCI WOS
Document Type
Review
Abstract
Despite the introduction of statins for lowering LDL-C level, atherosclerotic cardiovascular disease (ASCVD) remains a leading cause of death and morbidity worldwide. Combination therapies with statin and other lipid-lowering drugs, including ezetimibe and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, have unlocked additive benefits for treatment of ASCVD, but morbidity and mortality due to ASCVD remain high. New anti-inflammatory therapies have emerged for treatment and prevention of ASCVD to address these problems. Canakinumab neutralization of interleukin-1 beta (IL-1 beta) is the only verified therapy, and low-dose methotrexate holds promise due to its efficacy and safety for treatment of ASCVD. However, many agonistic and antagonistic candidates within inflammation pathways have failed to develop into useful drugs for ASCVD because of the complexity of the inflammatory process in atherosclerosis. In this review, we outline current and future pharmaceutical therapies for ASCVD in terms of lipid-modifying strategies and anti-inflammation treatments.
DOI
10.1007/s12272-019-01116-1
Appears in Collections:
자연과학대학 > 생명과학전공 > Journal papers
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE